What is the current stock price of Phathom Pharmaceuticals, Inc. (PHAT)?

As of the latest market data, Phathom Pharmaceuticals, Inc. (PHAT) is trading at $12.63. The stock has seen a loss of -0.08% today.

Does Phathom Pharmaceuticals, Inc. (PHAT) pay a dividend?

Based on current data, Phathom Pharmaceuticals, Inc. does not have a confirmed active dividend policy.

What is the market cap of Phathom Pharmaceuticals, Inc.?

The current market capitalization of Phathom Pharmaceuticals, Inc. (PHAT) is approximately unavailable.

PHAT

Phathom Pharmaceuticals, Inc.·Healthcare

12.63

0.079%(−0.01)

Market Closed

14.36

13.698%(+1.73)

After Hours

Last Updated: — ET

52W L: $2.2152W H: $18.31

PHAT NEWS

globenewswire.com

5d ago

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

FLORHAM PARK, N.J., April 06, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following upcoming investor conferences in April: Raymond James 2026 Biotech Innovation Symposium in New York, NY Date: Tuesday, April 14, 2026 Management to participate in one-on-one meetings throughout the conference 25th Annual Needham Virtual Healthcare Conference Date: Wednesday, April 15, 2026Fireside Chat: 1:30 pm EDT Management to participate in one-on-one meetings throughout the conference To access the live webcast and archived recording of the event, visit the News & Events section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations.

247wallst.com

Mar 27

Phathom Pharmaceuticals Upgraded by Barclays to Overweight With $18 Target

Barclays analyst Jenna Davidner upgraded Phathom Pharmaceuticals (NASDAQ:PHAT) to Overweight from Equal Weight on Friday, raising her price target to $18 from $16.

defenseworld.net

Mar 23

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Receives $22.25 Consensus PT from Brokerages

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the nine ratings firms that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, five have issued a buy rating and one

seekingalpha.com

Mar 11

Phathom Pharmaceuticals, Inc. (PHAT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

seekingalpha.com

Feb 26

Phathom Pharmaceuticals, Inc. (PHAT) Q4 2025 Earnings Call Transcript

zacks.com

Feb 26

Phathom Pharmaceuticals, Inc. (PHAT) Reports Q4 Loss, Beats Revenue Estimates

Phathom Pharmaceuticals, Inc. (PHAT) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to a loss of $0.79 per share a year ago.

Company Profile

Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Sector

Healthcare

Industry

Biotechnology

Employees

427

IPO Date

2019-10-25

Beta

0.61

Websitewww.phathompharma.com↗